Oncotarget

Research Papers:

Identifying the determinants of response to MDM2 inhibition

Anne Y. Saiki _, Sean Caenepeel, Elissa Cosgrove, Cheng Su, Michael Boedigheimer and Jonathan D. Oliner

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:7701-7712. https://doi.org/10.18632/oncotarget.3116

Metrics: PDF 1348 views  |   HTML 1644 views  |   ?  


Abstract

Anne Y. Saiki1, Sean Caenepeel1, Elissa Cosgrove2,5, Cheng Su3, Michael Boedigheimer4, Jonathan D. Oliner1

1Oncology Research, Amgen, Inc., Thousand Oaks, California, USA

2Genome Analysis Unit, Amgen, Inc., South San Francisco, California, USA

3Biostatistics, Amgen, Inc., Seattle, Washington, USA

4Molecular Sciences, Amgen, Inc., Thousand Oaks, California, USA

5Department of Molecular Biology and Genetics, Cornell University, Ithaca, New York, USA

Correspondence to:

Jonathan D. Oliner, e-mail: jonoliner@hotmail.com

Keywords: TP53, MDM2, amplification

Received: October 28, 2014     Accepted: January 08, 2015     Published: February 03, 2015

ABSTRACT

Previous reports have provided evidence that p53 mutation is a strong negative predictor of response to MDM2 inhibitors. However, this correlation is not absolute, as many p53Mutant cell lines have been reported to respond to MDM2 inhibition, while many p53WT cell lines have been shown not to respond. To better understand the nature of these exceptions, we screened a panel of 260 cell lines and noted similar discrepancies. However, upon extensive curation of this panel, these apparent exceptions could be eliminated, revealing a perfect correlation between p53 mutational status and MDM2 inhibitor responsiveness. It has been suggested that the MDM2-amplified subset of p53WT tumors might be particularly sensitive to MDM2 inhibition. To facilitate clinical testing of this hypothesis, we identified a rationally derived copy number cutoff for assignment of functionally relevant MDM2 amplification. Applying this cutoff resulted in a pan-cancer MDM2 amplification rate far lower than previously published.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3116